These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23567085)

  • 21. Cannabinoid receptors as therapeutic targets in the management of liver diseases.
    Mallat A; Lotersztajn S
    Drug News Perspect; 2008 Sep; 21(7):363-8. PubMed ID: 19259549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the endocannabinoid system as an anticancer target.
    Malfitano AM; Ciaglia E; Gangemi G; Gazzerro P; Laezza C; Bifulco M
    Expert Opin Ther Targets; 2011 Mar; 15(3):297-308. PubMed ID: 21244344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabinoid receptors in the kidney.
    Hryciw DH; McAinch AJ
    Curr Opin Nephrol Hypertens; 2016 Sep; 25(5):459-64. PubMed ID: 27367912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases.
    Wang M; Meng N; Chang Y; Tang W
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1488-501. PubMed ID: 27100518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocannabinoid System Contributes to Liver Injury and Inflammation by Activation of Bone Marrow-Derived Monocytes/Macrophages in a CB1-Dependent Manner.
    Mai P; Yang L; Tian L; Wang L; Jia S; Zhang Y; Liu X; Yang L; Li L
    J Immunol; 2015 Oct; 195(7):3390-401. PubMed ID: 26320250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
    Janero DR; Makriyannis A
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions Between Alcohol and the Endocannabinoid System.
    Kunos G
    Alcohol Clin Exp Res; 2020 Apr; 44(4):790-805. PubMed ID: 32056226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.
    Tam J
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):267-76. PubMed ID: 26280171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.
    Baldassarre M; Giannone FA; Napoli L; Tovoli A; Ricci CS; Tufoni M; Caraceni P
    Liver Int; 2013 Oct; 33(9):1298-308. PubMed ID: 23890208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: past, present and future.
    Simon V; Cota D
    Eur J Endocrinol; 2017 Jun; 176(6):R309-R324. PubMed ID: 28246151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of endocannabinoid 1 and 2 (CB1; CB2) receptor agonists on luteal weight, circulating progesterone, luteal mRNA for luteinizing hormone (LH) receptors, and luteal unoccupied and occupied receptors for LH in vivo in ewes.
    Tsutahara NM; Weems YS; Arreguin-Arevalo JA; Nett TM; LaPorte ME; Uchida J; Pang J; McBride T; Randel RD; Weems CW
    Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):17-24. PubMed ID: 21109016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
    Vemuri VK; Janero DR; Makriyannis A
    Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the endocannabinoid system in drug addiction.
    Manzanares J; Cabañero D; Puente N; García-Gutiérrez MS; Grandes P; Maldonado R
    Biochem Pharmacol; 2018 Nov; 157():108-121. PubMed ID: 30217570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
    Hungund BL; Basavarajappa BS
    Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis.
    Bazwinsky-Wutschke I; Zipprich A; Dehghani F
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.
    Shi D; Zhan X; Yu X; Jia M; Zhang Y; Yao J; Hu X; Bao Z
    Lipids Health Dis; 2014 Nov; 13():173. PubMed ID: 25406988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis.
    Giannone FA; Baldassarre M; Domenicali M; Zaccherini G; Trevisani F; Bernardi M; Caraceni P
    Lab Invest; 2012 Mar; 92(3):384-95. PubMed ID: 22184091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease.
    Cappellano G; Uberti F; Caimmi PP; Pietronave S; Mary DA; Dianzani C; Micalizzi E; Melensi M; Boldorini R; Nicosia G; Crosio E; Chiocchetti A; Aina F; Prat M; Dianzani U; Vacca G; Ariatti C; Grossini E
    Can J Cardiol; 2013 Apr; 29(4):499-509. PubMed ID: 22926037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B.
    Dai E; Zhang L; Ye L; Wan S; Feng L; Qi Q; Yao F; Li Z
    Int J Infect Dis; 2017 Jun; 59():124-130. PubMed ID: 28315398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.